MapLight Therapeutics, Inc., was incorporated under the laws of the State of Delaware in November 2018. The company is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases. Its lead drug candidate, ML-007C-MA, is a fixed-dose compound muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis and is currently in Phase 2 trials. The company is also developing ML-004 for the treatment of autism spectrum disorder social communication disorder. 

MPLT

MPLT Profile